	Item No	Recommendation
		(a) Indicate the study's design with a commonly used term in the title or
Title and abstract	1	the abstract
	1	(b) Provide in the abstract an informative and balanced summary of what
		was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of
		recruitment, exposure, follow-up, and data collection
Participants	6	( <i>a</i> ) Give the eligibility criteria, and the sources and methods of selection of
		participants
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders,
		and effect modifiers. Give diagnostic criteria, if applicable
		For each variable of interest, give sources of data and details of methods
Data sources/	8*	of assessment (measurement). Describe comparability of assessment
measurement	0	methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Study Size	10	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
		( <i>a</i> ) Describe all statistical methods, including those used to control for
	12	confounding (b) Describe any methods used to examine subgroups and interactions
		(b) Describe any methods used to examine subgroups and interactions
Statistical methods		(c) Explain how missing data were addressed
		( <i>d</i> ) If applicable, describe analytical methods taking account of sampling
		strategy
		( <u>e</u> ) Describe any sensitivity analyses
Results		
		(a) Report numbers of individuals at each stage of study—eg numbers
		potentially eligible, examined for eligibility, confirmed eligible, included
Participants	13*	in the study, completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
	14*	(a) Give characteristics of study participants (eg demographic, clinical,
Descriptive data		social) and information on exposures and potential confounders
Descriptive data		(b) Indicate number of participants with missing data for each variable of
		interest
Outcome data	15*	Report numbers of outcome events or summary measures
		(a) Give unadjusted estimates and, if applicable, confounder-adjusted
		estimates and their precision (eg, 95% confidence interval). Make clear
Main results	16	which confounders were adjusted for and why they were included
Main results	16	which confounders were adjusted for and why they were included(b) Report category boundaries when continuous variables were
Main results	16	<ul><li>which confounders were adjusted for and why they were included</li><li>(b) Report category boundaries when continuous variables were categorized</li></ul>
Main results	16	which confounders were adjusted for and why they were included(b) Report category boundaries when continuous variables were

		and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
		Discuss limitations of the study, taking into account sources of potential
Limitations	19	bias or imprecision. Discuss both direction and magnitude of any
		potential bias
		Give a cautious overall interpretation of results considering objectives,
Interpretation	20	limitations, multiplicity of analyses, results from similar studies, and other
		relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information		
Funding		Give the source of funding and the role of the funders for the present
	22	study and, if applicable, for the original study on which the present article
		is based

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.